既往被拒绝移植的PGT-A活检异常胚胎的IVF结局:一项前瞻性队列研究
该前瞻性队列纳入69对夫妇,自2014年起将其他机构拒绝移植的444枚PGT-A异常胚胎转至本中心,其中50例患者已进行57个移植周期共141枚胚胎。移植后获得8例活产、11例流产,无自愿终止妊娠。
要点
- 许多夫妇在仅有PGT-A异常胚胎时愿意移植,此类移植可获得持续妊娠和活产。
- 移植的144枚胚胎中,102枚(72.3%)仅有1或2个染色体异常,30枚(21.3%)有3个及以上,9枚(6.4%)因DNA降解为「未诊断」。
- 结果包括8例活产、11例流产,1例新生儿因节段性重复需修复主动脉缩窄。
核心结论
- 许多仅有PGT-A异常胚胎的夫妇愿意移植这些胚胎,此类移植可建立持续妊娠和活产。
研究设计与样本
- 前瞻性队列研究,自2014年起纳入69对夫妇,将既往被原机构拒绝移植的444枚PGT-A异常胚胎转至本中心。
- 其中50例患者已进行57个移植周期,共移植141枚胚胎。
- 胚胎在其他机构通过PGT-A(主要使用下一代测序)诊断为异常。
- 取卵时女性年龄为41.35 ± 3.98岁,74%为白人,12%为亚裔,10%为非裔。
主要发现
- 移植的144枚胚胎中,102枚(72.3%)仅有1或2个染色体异常,30枚(21.3%)有3个及以上,9枚(6.4%)因DNA降解为「未诊断」但仍被拒绝移植。
- 移植PGT-A异常胚胎后获得8例活产、11例流产,无自愿终止妊娠。
- 1例新生儿出生时伴有节段性重复,需修复主动脉缩窄。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本病例系列中的夫妇是在其他机构被拒绝移植后选择移植胚胎的,可能不能代表更广泛接受PGT-A的IVF夫妇群体。
- 并非所有异常表型在出生后即刻出现,因此继续随访这些儿童的发育很重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the outcomes for patients who choose to move embryos diagnosed as abnormal by preimplantation genetic testing for aneuploidy (PGT-A) to a new institution for transfer after the diagnosing institution refused to transfer them? SUMMARY ANSWER: Many patients seek to have selected embryos with PGT-A abnormal trophectoderm biopsies transferred recognizing that these embryos can still offer a chance of pregnancy and live birth. WHAT IS KNOWN ALREADY: : PGT-A is a widely practiced method of selecting embryos for transfer based on biopsy of a few cells. Many clinical practices refuse to transfer PGT-A abnormal embryos even when there are no other 'normal' embryos available. STUDY DESIGN, SIZE, DURATION: This is a prospective cohort of 69 couples who, since 2014, moved a total of 444 PGT-A abnormal embryos previously refused transfer at their parent institutions to our practice. Among these, 50 patients have, thus far, undergone 57 transfer cycles of 141 embryos. PARTICIPANTS/MATERIALS, SETTING, METHODS: Embryos diagnosed at other institutions by PGT-A as abnormal (mostly using next generation sequencing) were moved to our academically affiliated private fertility and research center in New York City. Female age at retrieval was 41.35 ± 3.98 years, 74% were Caucasian, 12% Asian and 10% were of African descent. All embryos identified as PGT-A abnormal among prospectively identified couples were recorded in our center's registry. MAIN RESULTS AND THE ROLE OF CHANCE: Among the 144 embryos transferred 102 (72.3%) had only 1 or 2 chromosomal abnormalities, 30 (21.3%) had 3 or more and 9 (6.4%) were 'undiagnosed' because of degraded DNA, yet still had been refused transfer. Transfer of PGT-A abnormal embryos resulted in 8 live births, 11 miscarriages and no voluntary terminations. One child was born with a segmental duplication and required repair of coarctation of the aorta as a newborn. Many couples with only PGT-A abnormal embryos are willing to have their PGT-A abnormal embryos transferred and such transfers can result in the establishment of ongoing euploid pregnancies and live births. LIMITATIONS, REASONS FOR CAUTION: Findings in this case series represent couples who chose to have their embryos transferred after having been refused transfer elsewhere and may not be representative of the wider population of couples undergoing IVF with PGT-A in general. Not all abnormal phenotypes present in the immediate postnatal period so it will be important to continue to follow the development of these children. WIDER IMPLICATIONS OF THE FINDINGS: PGT-A can result in a clinics refusal to transfer embryos with abnormal PGT-A biopsies, even those with mosaic findings, consequently large numbers of infertile women are prematurely advised that their only chance of motherhood is through third-party egg-donation. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by intramural funds from the Center for Human Reproduction and the not-for-profit research Foundation for Reproductive Medicine, both in New York, NY, USA. N.G. and D.H.B. are listed as co-inventors on several U.S. patents. One of these patents (US Patent# 7,615,544) relates to pre-supplementation of hypo-androgenic infertile women with androgens, such as DHEA and testosterone and, therefore, at least peripherally related to the subject of this manuscript. N.G. and D.F.A. also received travel funds and speaker honoraria from several pharmaceutical and medical device companies, though none related to the here presented subject and manuscript. N.G. is a shareholder in Fertility Nutraceuticals and he and D.H.B. receive royalty payments from Fertility Nutraceuticals LLC. TRIAL REGISTRATION NUMBER: N/A.
引用
- Barad DH, Albertini DF, Molinari E, et al. IVF outcomes of embryos with abnormal PGT-A biopsy previously refused transfer: a prospective cohort study. Hum Reprod. 2022. PMID: 35413106. doi:10.1093/humrep/deac063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。